Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;10(10):581-92.
doi: 10.1038/nrrheum.2014.64. Epub 2014 May 27.

Mechanisms, impact and management of pain in rheumatoid arthritis

Affiliations
Review

Mechanisms, impact and management of pain in rheumatoid arthritis

David A Walsh et al. Nat Rev Rheumatol. 2014 Oct.

Abstract

People with rheumatoid arthritis (RA) identify pain as their most important symptom, one that often persists despite optimal control of inflammatory disease. RA pain arises from multiple mechanisms, involving inflammation, peripheral and central pain processing and, with disease progression, structural change within the joint. Consequently, RA pain has a wide range of characteristics-constant or intermittent, localized or widespread-and is often associated with psychological distress and fatigue. Dominant pain mechanisms in an individual are identified by critical evaluation of clinical symptoms and signs, and by laboratory and imaging tests. Understanding these mechanisms is essential for effective management, although evidence from preclinical models should be interpreted with caution. A range of pharmacological analgesic and immunomodulatory agents, psychological interventions and surgery may help manage RA pain. Pain contributes importantly to the clinical assessment of inflammatory disease activity, and noninflammatory components of RA pain should be considered when gauging eligibility for or response to biologic agents. Further randomized controlled trials are required to determine the optimal usage of analgesics in RA, and novel agents with greater efficacy and lower propensity for adverse events are urgently needed. Meanwhile, targeted use of existing treatments could reduce pain in people with RA.

PubMed Disclaimer

References

    1. Br J Sports Med. 2011 Sep;45(12):1008-9 - PubMed
    1. Nat Rev Rheumatol. 2013 Nov;9(11):654-64 - PubMed
    1. Brain Behav Immun. 2011 Jan;25(1):6-13 - PubMed
    1. Int J Clin Pharmacol Res. 1991;11(6):261-6 - PubMed
    1. Pain Physician. 2013 Mar-Apr;16(2):E61-70 - PubMed